Osteoporosis: Now and the future

Tilman D. Rachner, Sundeep Khosla, Lorenz C. Hofbauer

Research output: Contribution to journalArticle

1063 Citations (Scopus)

Abstract

Osteoporosis is a common disease characterised by a systemic impairment of bone mass and microarchitecture that results in fragility fractures. With an ageing population, the medical and socioeconomic effect of osteoporosis, particularly postmenopausal osteoporosis, will increase further. A detailed knowledge of bone biology with molecular insights into the communication between bone-forming osteoblasts and bone-resorbing osteoclasts and the orchestrating signalling network has led to the identification of novel therapeutic targets. Novel treatment strategies have been developed that aim to inhibit excessive bone resorption and increase bone formation. The most promising novel treatments include: denosumab, a monoclonal antibody for receptor activator of NF-κB ligand, a key osteoclast cytokine; odanacatib, a specific inhibitor of the osteoclast protease cathepsin K; and antibodies against the proteins sclerostin and dickkopf-1, two endogenous inhibitors of bone formation. This overview discusses these novel therapies and explains their underlying physiology.

Original languageEnglish (US)
Pages (from-to)1276-1287
Number of pages12
JournalThe Lancet
Volume377
Issue number9773
DOIs
StatePublished - Apr 9 2011

Fingerprint

Osteoporosis
Osteoclasts
Bone and Bones
Osteogenesis
Cathepsin K
Endopeptidase K
Postmenopausal Osteoporosis
Bone Resorption
Osteoblasts
Molecular Biology
Monoclonal Antibodies
Cytokines
Ligands
Antibodies
Therapeutics
Population
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011). Osteoporosis: Now and the future. The Lancet, 377(9773), 1276-1287. https://doi.org/10.1016/S0140-6736(10)62349-5

Osteoporosis : Now and the future. / Rachner, Tilman D.; Khosla, Sundeep; Hofbauer, Lorenz C.

In: The Lancet, Vol. 377, No. 9773, 09.04.2011, p. 1276-1287.

Research output: Contribution to journalArticle

Rachner, TD, Khosla, S & Hofbauer, LC 2011, 'Osteoporosis: Now and the future', The Lancet, vol. 377, no. 9773, pp. 1276-1287. https://doi.org/10.1016/S0140-6736(10)62349-5
Rachner, Tilman D. ; Khosla, Sundeep ; Hofbauer, Lorenz C. / Osteoporosis : Now and the future. In: The Lancet. 2011 ; Vol. 377, No. 9773. pp. 1276-1287.
@article{83238365d3b04d13b657eb11e49eef98,
title = "Osteoporosis: Now and the future",
abstract = "Osteoporosis is a common disease characterised by a systemic impairment of bone mass and microarchitecture that results in fragility fractures. With an ageing population, the medical and socioeconomic effect of osteoporosis, particularly postmenopausal osteoporosis, will increase further. A detailed knowledge of bone biology with molecular insights into the communication between bone-forming osteoblasts and bone-resorbing osteoclasts and the orchestrating signalling network has led to the identification of novel therapeutic targets. Novel treatment strategies have been developed that aim to inhibit excessive bone resorption and increase bone formation. The most promising novel treatments include: denosumab, a monoclonal antibody for receptor activator of NF-κB ligand, a key osteoclast cytokine; odanacatib, a specific inhibitor of the osteoclast protease cathepsin K; and antibodies against the proteins sclerostin and dickkopf-1, two endogenous inhibitors of bone formation. This overview discusses these novel therapies and explains their underlying physiology.",
author = "Rachner, {Tilman D.} and Sundeep Khosla and Hofbauer, {Lorenz C.}",
year = "2011",
month = "4",
day = "9",
doi = "10.1016/S0140-6736(10)62349-5",
language = "English (US)",
volume = "377",
pages = "1276--1287",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9773",

}

TY - JOUR

T1 - Osteoporosis

T2 - Now and the future

AU - Rachner, Tilman D.

AU - Khosla, Sundeep

AU - Hofbauer, Lorenz C.

PY - 2011/4/9

Y1 - 2011/4/9

N2 - Osteoporosis is a common disease characterised by a systemic impairment of bone mass and microarchitecture that results in fragility fractures. With an ageing population, the medical and socioeconomic effect of osteoporosis, particularly postmenopausal osteoporosis, will increase further. A detailed knowledge of bone biology with molecular insights into the communication between bone-forming osteoblasts and bone-resorbing osteoclasts and the orchestrating signalling network has led to the identification of novel therapeutic targets. Novel treatment strategies have been developed that aim to inhibit excessive bone resorption and increase bone formation. The most promising novel treatments include: denosumab, a monoclonal antibody for receptor activator of NF-κB ligand, a key osteoclast cytokine; odanacatib, a specific inhibitor of the osteoclast protease cathepsin K; and antibodies against the proteins sclerostin and dickkopf-1, two endogenous inhibitors of bone formation. This overview discusses these novel therapies and explains their underlying physiology.

AB - Osteoporosis is a common disease characterised by a systemic impairment of bone mass and microarchitecture that results in fragility fractures. With an ageing population, the medical and socioeconomic effect of osteoporosis, particularly postmenopausal osteoporosis, will increase further. A detailed knowledge of bone biology with molecular insights into the communication between bone-forming osteoblasts and bone-resorbing osteoclasts and the orchestrating signalling network has led to the identification of novel therapeutic targets. Novel treatment strategies have been developed that aim to inhibit excessive bone resorption and increase bone formation. The most promising novel treatments include: denosumab, a monoclonal antibody for receptor activator of NF-κB ligand, a key osteoclast cytokine; odanacatib, a specific inhibitor of the osteoclast protease cathepsin K; and antibodies against the proteins sclerostin and dickkopf-1, two endogenous inhibitors of bone formation. This overview discusses these novel therapies and explains their underlying physiology.

UR - http://www.scopus.com/inward/record.url?scp=79953751008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953751008&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)62349-5

DO - 10.1016/S0140-6736(10)62349-5

M3 - Article

C2 - 21450337

AN - SCOPUS:79953751008

VL - 377

SP - 1276

EP - 1287

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9773

ER -